

CURRICULUM VITAE

Bernard A. Fischer, IV, M.D. (Bernie)
Assistant Professor, Department of Psychiatry, Maryland Psychiatric Research Center
University of Maryland School of Medicine

Date

February, 2015.

Contact Information

Maryland Psychiatric Research Center
P.O. Box 21247
Baltimore, Maryland 21228
(410) 402-7113; fax (410) 402-7198
bfischer@mprc.umaryland.edu

Education

- 08/1993-05/1997 **Undergraduate Degree:** The University of Maryland, Baltimore County (UMBC); B.A. in Psychology: Biopsychology Track. Awarded *magna cum laude* 5/21/97.
- 07/1997-08/1998 **Graduate Degree:** The University of Maryland Graduate School; M.A. in Applied and Professional Ethics: Bioethics and the Ethics of Healthcare Track. Awarded 8/31/98.
- 08/1998-05/2002 **Medical Degree:** The Medical College of Virginia, Virginia Commonwealth University (MCV/VCU); M.D. degree. Matriculated 8/12/98, Awarded 5/18/02.

Post-Graduate Education and Training

- 07/2002-06/2007 **Residency:** The University of Maryland / Sheppard Pratt Residency in Psychiatry, Research Track. National Institute of Mental Health (NIMH)-Funded (R25) Five-Year Clinical/Research Training Program. Completed 6/30/07 (Board Eligible 6/30/06).
- 09/2005-05/2006 Statistics for Biomedical Scientists I & II (STAT 500M), Foundation for Advanced Education in the Sciences (FAES) Graduate School at the National Institutes of Health (NIH).
- 07/2007-06/2009 **Post-Doctoral Fellowship:** NIMH-Funded (T32) Multidisciplinary Schizophrenia Research Fellowship at the Maryland Psychiatric Research Center (MPRC), University of Maryland School of Medicine. Completed 6/30/09.

Certification

Diplomat, American Board of Psychiatry and Neurology (ABPN); Number 57114; Certified 2007.

Diplomat, American Board of Addiction Medicine (ABAM); Number 2010163; Certified 2010.

DEA-Recognized Waiver for Prescribing Narcotics for Maintenance or Detoxification
(allows prescription of buprenorphine in an office-based setting); Certified 2006.

Medical Licensure

State of Maryland; Active since 12/9/04.

Military Service

- 03/2012-present Direct Commissioned Officer, Medical Corps, United States Navy (Reserve Component).
Current Rank: Lieutenant Commander (O-4)
Gaining Command: Expeditionary Medicine Facility (EMF)- Great Lakes One.
Cross-Assigned for Drills: Detachment I (Navy Operational Support Center, Baltimore, Maryland), Expeditionary Medicine Facility (EMF)- Bethesda.
- 01/2014-10/2014 Deployment: Operation Enduring Freedom (OEF), Psychiatrist, Mental Health Department, NATO Role III Multinational Medical Unit, Kandahar Airfield, Kandahar, Afghanistan.

Employment History

- 10/1999-05/2002 Clinical Instructor, Part-time, Medical Ethics; Virginia Commonwealth University, Medical College of Virginia School of Medicine (Richmond, Virginia).
- 07/2005-06/2007 Chief Resident, Research and Academics; University of Maryland / Sheppard Pratt Psychiatry Residency Program (Baltimore, Maryland).
- 10/2006-06/2007 Clinical Instructor, Part-time; Department of Psychiatry, University of Maryland School of Medicine. Attending Psychiatrist at Walter P. Carter Center (State Psychiatric Hospital, Baltimore City; Facility Closed 2009).
- 07/2009-present Assistant Professor, Full-time; Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine (Baltimore, Maryland).
- 09/2009-present Investigator, Part-time (5/8); Mental Illness Research, Education, and Clinical Center (MIRECC), Capital Network (VISN 5); VA Maryland Health Care System; Department of Veterans Affairs (Baltimore, Maryland).
- 02/2010-09/2013 Credentialed Physician Contractor (Unpaid Position); National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), Department of Health and Human Services (Baltimore, Maryland).

Professional Memberships

- 1999-2012 American Psychiatric Association (APA).
- 2013-present Fellow, American Psychiatric Association (APA).
- 2002-present Maryland Psychiatric Society (MPS).
- 2007-present American Society of Addiction Medicine (ASAM).
- 2010-present Research Society on Alcoholism (RSA).
- 2012-present Reserve Officers Association (ROA) of the United States.

Honors and Awards

- 1993-1997 President's Fellow Academic Scholarship, UMBC.
- 1994 Psi Chi (The National Honor Society in Psychology), UMBC; Inducted 1994, Chapter Secretary 1995, Chapter Vice President 1996.
- 1995 Golden Key National Honor Society, UMBC.
- 1996 Phi Kappa Phi Honor Society, UMBC.
- 1997 Award for Distinguished Service to the Department of Psychology, UMBC.
- 2001 Dlin/Fischer Award for Significant Achievement in Clinical Research (Co-Recipient), Academy of Psychosomatic Medicine.
- 2004 Clarence G. Schulz Prize for Best Resident Paper, Sheppard Pratt.
- 2005-2006 Fellow, Group for Advancement of Psychiatry (GAP), Psychopharmacology Committee.
- 2006 Dr. Russell Monroe Award for Excellence in Research, University of Maryland/Sheppard Pratt Residency in Psychiatry.
- 2006 Irving J. Taylor, M.D. Prize in Psychiatry- Resident Research Award, University of Maryland School of Medicine.
- 2007 Guze Symposium on Alcoholism, Washington University, St. Louis, Travel Award.
- 2007 Ruth Fox Memorial Endowment Scholarship, American Society of Addiction Medicine.
- 2007 Selection to Research Colloquium for Junior Investigators, American Psychiatric Association Corresponding Committee on Research Training.
- 2007 NIMH New Investigator Award, New Clinical Drug Evaluation Unit (NCDEU) Meeting, NIMH/ American Society of Clinical Psychopharmacology (ASCP).
- 2007-2011 NIH Clinical Research Loan Repayment Program Award.
- 2008 Travel Award, American Society of Clinical Psychopharmacology (ASCP)/ NIMH/Zucker Hillside Hospital Workshop on Clinical Trials.
- 2009 Junior Faculty Travel Award to Conference "Toward Optimal Treatment for Schizophrenia and Co-Occurring Alcohol Use Disorders"; hosted by Dartmouth Medical School.

2010 Jarboe Research Award for Junior Faculty, University of Maryland School of Medicine.
 2011 Finalist, Passano Foundation Clinician-Investigator Award for Career Development.
 2012- 2014 IPI Department of Psychiatry Award for collaboration outside of assigned division.

Clinical Activities

Clinical expertise in the treatment of psychotic disorders: therapy (group, family, individual), psychoeducation, and psychopharmacology (including expertise prescribing clozapine).

Administrative Service

Institutional Service

1998 Ethics Consultant for the University of Maryland Medical Systems Institutional Review Board (IRB; chair: Paul Fishman, M.D., Ph.D.) on Genetics Research and Research with the Decisionally Impaired.

1999-2002 Founder/President of MCV's Bioethics, Art, and Medical Humanities Society (discussed ethics/humanism in medicine; organized medical student art show each spring).

2001 Representative for MCV/VCU Students to the LCME Reaccreditation Envoy.

2002 Student Professionalism Committee of Medical College of Virginia.

2003-2005 University of Maryland / Sheppard Pratt Psychiatry Residency Program Librarian.

2005-2006 Committee on Recruitment, University of Maryland/Sheppard Pratt Psychiatry Residency.

2005-2013 Interviewer for applicants to the University of Maryland/Sheppard Pratt Psychiatry Residency.

2005-2009 Coordinator, monthly Inpatient Adult Psychiatry Journal Club, University of Maryland / Sheppard Pratt Residency in Psychiatry.

2005-2006 Chair, Committee on Competency in Evidence-Based Medicine Requirement, University of Maryland / Sheppard Pratt Residency in Psychiatry.

2006-2008 Director, Evidence-Based Medicine Competency Project, University of Maryland / Sheppard Pratt Residency in Psychiatry.

2008-2013 Discussant, Psychotic Disorders Seminar, Program of Assertive Community Treatment (PACT), Department of Psychiatry, University of Maryland School of Medicine.

2009 Committee on Expansion of the First Episode Clinic of MPRC.

2010-2013 Faculty Representative to the MPRC Chiefs' Meeting (liaison between the MPRC program chiefs and the larger MPRC faculty).

2011-present Director, Psychopharmacology Clinic, Capital Network (VISN 5) MIRECC; Department of Veterans Affairs.

2011-present Scientific Director, Capital Network (VISN 5) MIRECC Pilot Grant Program; Department of Veterans Affairs.

2012-2013 Capital Network (VISN 5) MIRECC Research Post-Doctoral Fellowship Selection Committee; Department of Veterans Affairs.

2012-2014 Elected Representative to University of Maryland School of Medicine Council, Psychiatry Department (1 year as alternate, 1 year as representative).

National and International Service

ad hoc Journal/Book Reviewer Oxford University Press.
American Family Physician.
American Journal of Psychiatry.
Asian Journal of Psychiatry
Clinical Schizophrenia and Related Psychoses.
Comprehensive Psychiatry
International Archives of Medicine.
Journal of Affective Disorders.
Journal of Clinical Epidemiology.
Journal of Clinical Psychiatry.
Journal of Nervous and Mental Disease.
Neuropsychiatric Disease and Treatment.
Neuropsychiatry.
Neuropsychopharmacology.

ad hoc Journal/Book Reviewer (con't)

Schizophrenia Bulletin.
Schizophrenia Research.

ad hoc Grant Reviewer National Institute for Social Care and Health Research (NISCHR), Research for Patient and Public Benefit (RfPPB), Wales, United Kingdom.

2005-present Maryland Team Member, NAMI Walks for the Mind of America (Raising awareness of stigma against mental illness and money to support the National Alliance on Mental Illness).

2010 Co-Organizer/Moderator (with Russell L. Margolis, MD of Johns Hopkins University School of Medicine) of NARSAD's "Healthy Minds Across America" National Series of Symposia on Mental Health Research, Maryland Site.

Teaching/Supervisory Service

Supervision/Mentoring

2007-2012 Supervisor/Mentor, University of Maryland, Baltimore County- The Shriver Center, Undergraduate Interns; Supervision during 120 hours of service, 16 contact hrs/semester. Praveen George; 2007 Fall Semester; Mentor 2007-2010.
[University of Maryland School of Medicine, Internal Medicine Residency.] Daniel Slack; 2011 Spring Semester.
[Pre-Medical Studies, UMBC, anticipated graduation Spring 2012.] Madhu Karamsetty; 2012 Spring Semester.
[Independent Study: Neuroscience, UMBC, anticipated graduation 2015.]

2008-2012 Mentor, Howard County Public Schools Gifted and Talented Program, High School Students Aneesha Garg; Supervision during 250 hrs service, Academic Year 2008-09. Alison Murphy; Supervision during 250 hrs service, Academic Year 2009-10. Danielle Walker: Mentor, Senior Independent Study Project, Academic Year 2010-2011. Eric Seung Won Park, Supervision during 250 hrs service, Academic Year 2011-2012.

2009-2013 Psychotherapy Supervisor, University of Maryland/Sheppard Pratt Residency in Psychiatry. 1 hr/wk; PGY1-PGY3 Residents.

2012-present Clinical Skills Verification Examiner (required exam in order to sit for American Board of Psychiatry and Neurology), American Association of Directors of Psychiatric Residency Training (AADPRT) version of assessment.

Medical Student Teaching

2003-2013 Interviewer and Small Group Facilitator, "The Mental Status Exam", University of Maryland School of Medicine: Psychiatry/Neurosciences Course, MS-2; 6 contact hrs/yr.

2005-2010 Lecturer and Patient Interviewer, "The Mental Status Exam", Spring Grove State Hospital Clinical Case Conference, Senior Medical Students; 5 contact hrs/yr.

2007-2009 Lecturer, "Psychiatric Research", University of Maryland School of Medicine: Psychiatry Clerkship; MS-3; 12 contact hrs/yr.

2007-2012 Lecturer, PSYH 548 (Combined Accelerated Program in Psychiatry [CAPP]); Maryland Psychiatric Research Center mini-Elective; MS-2; 2 contact hrs/yr.

Graduate Student Teaching

2008-2012 Lecturer, "Psychiatric Ethics", University of Maryland, Baltimore, Graduate Program in Life Sciences, Biological Psychiatry Course (GPLS 781); 1.5 contact hrs.

- 2008-2012 Lecturer, "Schizophrenia: An Introduction to a Uniquely Human Condition", University of Maryland, Baltimore, Graduate Program in Life Sciences, Biological Psychiatry Course (GPLS 781); 1.5 contact hrs.
- 2008-2012 Lecturer, "Domains of Psychopathology: A Tool for Understanding Schizophrenia", University of Maryland, Baltimore, Graduate Program in Life Sciences, Biological Psychiatry Course (GPLS 781); 1.5 contact hrs/biennially.
- 2013 Lecturer, "RDoC Initiative: NIMH's Research Domain Criteria", University of Maryland, Baltimore, Graduate Program in Life Sciences, Biological Psychiatry Course (GPLS 781); 1 contact hr.

Psychiatry Resident Teaching

- 2007 Lecturer, "Advanced Antipsychotics", University of Maryland/Sheppard Pratt Residency in Psychiatry, PGY4 Psychiatry Residents; 3 contact hours.
- 2008-2013 Coursemaster & Lecturer, "Advanced Psychopharmacology" Course, University of Maryland /Sheppard Pratt Residency in Psychiatry, PGY4 Psychiatry Residents; 6 contact hrs/yr.
- 2010-2013 Coursemaster & Lecturer, "Introduction to Schizophrenia" Course, University of Maryland /Sheppard Pratt Residency in Psychiatry, PGY2 Psychiatry Residents; 8 contact hrs/yr.
- 2011-2013 "Special Topics" Lecturer invited by residents, "Quick Stats for Clinicians", University of Maryland /Sheppard Pratt Residency in Psychiatry, PGY4 Psychiatry Residents; 1 contact hr.
- 2011-2013 "Special Topics" Lecturer invited by residents, "Studies you should know", University of Maryland /Sheppard Pratt Residency in Psychiatry, PGY4 Psychiatry Residents; 1 contact hr.
- 2012-2013 Director, MPRC Senior Psychiatry Resident Research Electives for University of Maryland/Sheppard Pratt Residency Program in Psychiatry; Supervision of 2-5 PGY4 Residents/yr.
- 2013 Lecturer, "RDoC Initiative: NIMH's Research Domain Criteria", Neuroscience Course, PGY2 Psychiatry Residents; 1 contact hr.

Grants

Ongoing

06/01/2012-10/31/2015

CSP-576

Department of Veterans Affairs PIs: Mohamed & Zisook

VA Augmenting and Switching Treatments for Improving Depression Outcomes (VAST-D)

Determine whether switching antidepressant treatment to bupropion-SR, augmenting with bupropion-SR, or augmenting with aripiprazole will improve outcomes in Veterans with sub-optimal response to SSRI/SNRI treatment for depression.

Role: Baltimore Local Site Investigator Percent Effort: 20% (VA donated)

Completed

01/01/10-12/31/13

1I01CX000135-01A1 PI: Bennett (Original Awardee Dixon)

VA CSR&D

Total direct costs: \$587,552

Randomized Trial of a Smoking Cessation Program for Persons with SMI

This study tested a behavioral model of smoking cessation treatment to a standard approach to smoking cessation using a randomized controlled design.

Role: Co-Investigator Percent Effort: 2% (VA donated)

10/01/2011-09/30/213

CSP-572 PIs: Harvey & Siever
Department of Veterans Affairs

The Genetics of Functional Disability in Schizophrenia and Bipolar Illness

Determine whether certain genes are associated with functional disability within schizophrenia and/or bipolar illness.

Role: Baltimore Local Site Investigator Percent Effort: 20% (VA donated)

09/01/10 - 08/31/12

1R21DA027894-01 PI: Hahn

NIDA

Nicotinic Modulation of the Default Network of Resting Brain Function

Characterize effects of nicotinic agonism and antagonism on default network functioning and related cognitive performance using fMRI.

Role: Medically Accountable Investigator (MAI) Percent Effort: 2% (donated)

07/15/2011-07/14/2013

2011 NARSAD Young Investigator Award PI: Hahn

Default Network Dysfunction Underlying Visuospatial Attention Deficits in Schizophrenia

Determine whether a visuospatial attention abnormality previously described in schizophrenia is due to default network dysfunction.

Role: Medically Accountable Investigator (MAI) Percent Effort: 2% (donated)

09/01/2010-08/31/2012

VISN 5 MIRECC Pilot Grant PI: Fischer

Total Direct Costs: \$23,290

Topiramate for Alcohol Use Disorders in Veterans with Posttraumatic Stress Disorder

This project was a double-blind, placebo-controlled pilot of topiramate's effect on drinking behavior and PTSD symptoms in Veterans with both of these disorders. The project produced no analyzable data.

Role: PI Percent Effort: 10% (VA donated)

09/01/2009-08/31/2011

R03 AA019571 PI: Fischer

NIAAA- Support Opportunity for Addiction Research (SOAR) for New Investigators

Total Direct Costs: \$50,000

Glutamate Response to Acamprosate in Schizophrenia with Alcohol Misuse History

Baseline brain glutamate concentrations in people with schizophrenia who did and did not have a past history of alcohol abuse/dependence. Group differences in glutamate response to acamprosate was also measured.

Role: PI Percent Effort: 8%

09/01/09-08/31/2011

NIDA-MPRC Support Services Contract (N01DA59909, Contract PI Kelly) Co-PIs: Fischer, Gorelick

Risk Perception in Drug-Dependent Adults With and Without Schizophrenia

This project examined the perception of risks and risk-taking behavior during computer tasks of people with and without drug-dependence and with and without co-occurring schizophrenia.

Role: Co-PI Percent Effort: 10%

07/01/2008-06/30/2010

07/01/08-08/31/2011

2008 NARSAD Young Investigator Award (Peer-reviewed) PI: Fischer

Total Direct Costs: \$60,000 (No Indirect Costs Supported)

Clinical Trial and Neuroimaging Study of Acamprosate in Schizophrenia

This project evaluated acamprosate, a modulator of the glutamatergic system, in people with chronic schizophrenia. This pilot study evaluated the effects of acamprosate on symptoms, cognition, and proton magnetic resonance spectroscopy (¹H-MRS)-determined neurochemistry.

Role: PI Percent Effort: 2%

09/30/1999-5/31/2009

R01 MH 058898 PI: Carpenter

NIMH

Research Ethics in Schizophrenia

This project: 1. developed a new assessment instrument to determine capacity to consent to research, 2. evaluated the impact of a training exercise on capacity to consent, 3. monitored capacity to consent and retention of consent information during real-life clinical trials, 4. compared people with schizophrenia and controls on risk-taking computer tasks.

Role: Co-Investigator

Publications

Peer-Reviewed

1. Kavanagh BD, Fischer IV BA, Segreti EM, Wheelock JB, Boardman C, Roseff SD, Cardinale RM, Benedict SH, Goram AL. A cost analysis of erythropoietin versus blood transfusions for cervical cancer in patients receiving chemoradiotherapy. *Int J Radiat Oncol Biol Phys* 2001; 51 (2), 435-441. (PMID: 11567818).
2. Fischer IV BA. A summary of important documents in the field of research ethics. *Schizophr Bull* 2006; 32 (1), 69-80. (PMID: 16192409; PMCID: PMC2632196).
3. Kirkpatrick B, Fischer B. Subdomains within the negative symptoms of schizophrenia: Commentary. *Schizophr Bull* 2006; 32 (2): 246-9. (PMID: 16492798).
4. Sandson NB, Cozza KL, Armstrong SC, Eckermann G, Fischer BA, Phillips B. Med-Psych Drug-Drug Interactions Update: Clozapine Case Series. *Psychosomatics* 2007; 48:170-5. (PMID: 17329613).
5. Fischer BA, Weiner E. Clozapine levels lowered by modafinil: A case report and brief review of modafinil in schizophrenia. *Clin Schizophr Relat Psychoses* 2008; 2(1): 88-90.
6. Bhanji NH, Baron DA, Lacy BW, Gross LS, Goin MK, Sumner CR, Fischer BA, Slaby AE. Direct-to-consumer marketing: An attitude survey of psychiatric physicians. *Primary Psychiatry* 2008; 15(11):67-71.
7. Fischer BA, Carpenter Jr WT. Will the Kraepelinian dichotomy survive DSM-V? *Neuropsychopharmacology* 2009; 34(9):2081-7. (PMID: 19295511).
8. Buchanan RW, Kreyenbuhl J, Kelly D, Noel J, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W. The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements. *Schizophr Bull* 2010; 36(1):71-93. (PMID: 19955390; PMCID: PMC2800144).
9. Fischer BA, Boggs DL. The role of antihistaminic effects in the misuse of quetiapine: A case report and review of the literature. *Neurosci Biobehav Rev* 2010; 34(4):555-8. (PMID: 19896973).
10. Fischer BA, George P. The investigator and the IRB: A survey of depression and schizophrenia researchers. *Schizophr Res* 2010; 122(1-3):206-212. (PMID: 20064703; PMCID: PMC2895950).
11. Kirkpatrick B, Strauss G, Nguyen L, Fischer BA, Daniel DG, Cienfuegos A, Marder SR. The Brief Negative Symptom Scale: Psychometric properties. *Schizophr Bull* 2011; 37(2):300-5. (PMID: 20558531; PMCID: PMC3044634).
12. Keller WR, Fischer BA, Carpenter WT. Revisiting the diagnosis of schizophrenia: Where have we been and where are we going? *CNS Neurosci Ther* 2011; 17(2):83-8. (PMID: 21199450).
13. Fischer BA, Keller WR, Arango C, Pearlson G, McMahon RP, Meyer WA, Francis A, Kirkpatrick B, Carpenter WT, Buchanan RW. Cortical structural abnormalities in deficit versus nondeficit schizophrenia. *Schizophr Res* 2012; 136(1-3):51-4. (PMID: 22336954; PMCID: PMC3298625).

14. Fischer, BA. Maltreatment of people with serious mental illness in the early Twentieth Century: A focus on Nazi Germany and eugenics in America. *J Nerv Ment Dis* 2012; 200(12):1096-1100. (PMID: 23197125).
15. Strauss GP, Hong LE, Keller WR, Buchanan RW, Gold JM, Fischer BA, McMahon RP, Catalano LT, Culbreth AJ, Carpenter WT, Kirkpatrick B. Factor Structure of the Brief Negative Symptom Scale. *Schizophr Res* 2012; 142(1-3):96-8. (PMID: 23062750; PMCID: PMC3502636).
16. Fischer BA. A review of American psychiatry through its diagnoses: The history and development of the *Diagnostic and Statistical Manual of Mental Disorders*. *J Nerv Ment Dis* 2012; 200 (12):1022-30. (PMID: 23197117).
17. Strauss GP, Keller WR, Buchanan RW, Gold JM, Fischer BA, McMahon RP, Catalano LT, Culbreth AJ, Carpenter WT, Kirkpatrick B. Next-Generation Negative Symptom Assessment for Clinical Trials: Validation of the Brief Negative Symptom Scale. *Schizophr Res* 2012; 142(1-3):88-92. (PMID: 23127378; PMCID: PMC3502630).
18. Krishna N, Chiappelli J, Fischer BA, Knight S. Tacrolimus-induced paranoid delusions and fugue-like state. *Gen Hosp Psychiatry* 2013; 35(3):327.e5-327.e6. Epublished: doi:10.1016/j.genhosppsy.2012.07.010. (PMID: 22959421).
19. Krishna N, Fischer BA, Miller M, Register-Brown K, Patchan K, Hackman A. The Role of social media networks in psychotic disorders: A case report. *Gen Hosp Psychiatry* 2013; 35(5): 576.e1-2. Epublished: doi: 10.1016/j.genhosppsy.2012.10.006. (PMID: 23174460).
20. Strauss GP, Horan WP, Kirkpatrick B, Fischer BA, Keller WR, Miski P, Buchanan RW, Green MF, Carpenter WT. Deconstructing negative symptoms of schizophrenia: Avolition-apathy and emotional expression clusters predict clinical presentation and functional outcome. *J Psychiatric Res* 2013; 47(6):783-90. (PMID: 23453820).
21. Vidal C, Reese C, Chiappelli J, Fischer BA, Himelhoch S. Meta-analysis of efficacy of mirtazapine as an adjunctive treatment for negative symptoms in schizophrenia. *Clin Schizophr Relat Psychoses* 2013; Epublished ahead of print. (PMID: 23491969).
22. Fischer BA, McMahon RP, Meyer WA, Slack DJ, Appelbaum PS, Carpenter WT Jr. Participants with schizophrenia retain the information necessary for informed consent during clinical trials. *J Clin Psychiatry* 2013; 74(6):622-7. (PMID: 23842013).
23. Kelly DL, Wehring HJ, Earl AK, Sullivan K, Dickerson FB, Feldman S, McMahon RP, Buchanan RW, Warfel D, Keller WR, Fischer BA, Shim JC. Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin). *BMC Psychiatry* 2013; 13(1):214. Epublished ahead of print. (PMID: 23968123).
24. Keller WR, Vidal C, Park ES, Strauss GP, Fischer BA. The risk of diabetes in deficit schizophrenia. *Clin Schizophr Relat Psychoses* 2014; 7(4):235-7. (PMID: 23491970).
25. Keller WR, Fischer BA, McMahon R, Meyer W, Blake M, Buchanan RW. Community adherence to schizophrenia treatment and safety monitoring guidelines. *J Nerv Ment Dis* 2014; 202(1):6-12. (PMID: 24375205).
26. Fischer BA, McMahon RP, Kelly DL, Wehring HJ, Meyer WA, Feldman S, Carpenter WT, Gorelick DA. Risk-taking in schizophrenia and controls with and without cannabis dependence. *Schizophr Res* 2015; 161(2-3):4717. (PMID: 25467541).

27. Wijtenburg SA, Yang S, Fischer BA, Rowland LM. *In vivo* assessment of neurotransmitters and modulators with magnetic resonance spectroscopy: Application to schizophrenia. *Neurosci Biobehav Rev*, *In Press*. (PMID: 25614132).

Books & Book Chapters

1. Fischer, IV, B.A. & Carpenter, Jr., W.T. Remission, in *The Clinical Handbook of Schizophrenia*, Editors: Mueser, K. T. & Jeste, D.V., Guilford Publications, Inc., NY, 2008, pp. 559-65.
2. Fischer, IV, B.A., Kirkpatrick, B., Carpenter, Jr., W.T. The Neurobiology of Negative Symptoms and The Deficit Syndrome, in *The Handbook of Neurochemistry and Molecular Neurobiology*, Editor: Lajtha, A., 3rd edition; Volume 27: *Schizophrenia*, Volume Editors: Javitt, D.C. & Kantrowitz J.T., Springer Science and Business Media LLC, 2009, pp. 507-23.
3. Fischer, BA & Buchanan, RW. Schizophrenia: Clinical Manifestations, Assessment, Diagnosis, and Course. In: *UpToDate*, Basow, DS (Ed), UpToDate, Waltham, MA, 2014.
4. Fischer, BA & Buchanan, RW. Schizophrenia: Epidemiology and Pathogenesis. In: *UpToDate*, Basow, DS (Ed), UpToDate, Waltham, MA, 2014.

Published Abstracts

1. Provine RR, Fischer B, Taylor K: Ticklish relationships: An enigma resolved. *Soc Neuro Abstr* 1996; 22(1): 444. (Presented at the annual meeting of The Society for Neuroscience, Washington, DC.)
2. Olbrisch ME, Levenson JL, Kulstad J, Fischer, BA: Psychosocial evaluation criteria in U.S. liver transplant programs: A ten year update. *Liver Transplantation* 2003; 9(6): C56. (Presented at the joint annual meeting of the International Liver Transplant Society [ILTS] and the Liver Intensive Care Group of Europe [LICAGE], Barcelona, Spain.)
3. Fischer BA, Carpenter WT, Prentice KJ: Towards proof of ethical research in schizophrenia: Developing the modified Evaluation to Sign Consent. *Schizophr Bull* 2005; 31(S2): S483. (Presented at the Tenth International Congress on Schizophrenia Research, Savannah, GA.)
4. Fischer BA, Prentice KJ, Carpenter WT: The modified Evaluation to Sign Consent: Protection for clinical trials with vulnerable populations. *Biol Psychiatry* 2007; 61: 169s-170s. (Presented at the annual meeting of the Society for Biological Psychiatry, San Diego, CA.)
5. George P, Fischer BA: Investigator experiences with and opinions of IRBs. *Schizophr Bull* 2009; 35(S1): S344. (Presented at the Twelfth International Congress on Schizophrenia Research, San Diego, CA.)
6. Fischer BA, Prentice KJ, Mathews LC, Carpenter WT: Assessment of elements of consent over the course of real clinical trials in schizophrenia. *Schizophr Bull* 2009; 35(S1): S349. (Presented at the Twelfth International Congress on Schizophrenia Research, San Diego, CA.)
7. Prentice KJ, Gold JM, August SM, Fischer BA, Carpenter WT: Schizophrenia patients show altered processing of risk information in three decision-making tasks. *Schizophr Bull* 2009; 35(S1): S264. (Presented at the Twelfth International Congress on Schizophrenia Research, San Diego, CA.)
8. Buchanan RW, Kreyenbuhl J, Kelly D, Noel J, Fischer B, Boggs D, Aquino P, Fang B, Peterson E, Keller W. The 2009 Schizophrenia PORT psychopharmacological treatment recommendations. *Schizophr Bull* 2009; 35(S1): S129. (Presented at the Twelfth International Congress on Schizophrenia Research, San Diego, CA.)
9. Wehring H, Kelly DL, McMahon RP, Bordnick P, Bellack A, Holcomb HH, Fischer BA, Rowland LM, Turner H, Taylor R, Liu F, Heishman SJ. Assessment of tobacco craving in smokers with schizophrenia using virtual reality. *Schizophr Bull* 2011; 37(S1): S256. (Presented at the Thirteenth International Congress on Schizophrenia Research, Colorado Springs, CO.)

10. Fischer BA, Buchanan RW, Osing J, Holcomb HH, Rowland LM. Glutamate concentrations in the anterior cingulate vary based on past alcohol use. *Schizophr Bull* 2011; 37(S1): S124. (Presented at the Thirteenth International Congress on Schizophrenia Research, Colorado Springs, CO.)
11. Fischer BA, Keller WR, Vidal C, Park ES, Strauss GP. The risk of diabetes in deficit schizophrenia. *Schizophr Bull* 2013; 39(S1): S30-1. (Presented at the Fourteenth International Congress on Schizophrenia Research, Orlando, FL.)

Brief Communications

1. Fischer IV BA. [Review of the book *Acute and Transient Psychoses*]. *J Nerv Ment Dis* 2006; 194(3): 230.
2. Fischer IV BA. [Review of the book *Recovery from Schizophrenia*]. *J Nerv Ment Dis* 2008; 196(1): 84-5.
3. Fischer, BA. The unofficial myths of schizophrenia. [Invited editorial]. *J Nerv Ment Dis* 2012; 200(7):567-8. (PMID: 22759931).
4. Keller WR, Fischer BA, McMahon RP, Meyer W, Buchanan RW. Open-label salsalate for the treatment of pre-diabetes in people with schizophrenia [Letter to the Editor]. *Schizophr Res* 2013; 147(2-3): 408-9. (PMID: 23680037).
5. Fischer, BA. Schizophrenia research: Where are we? [Invited editorial]. *J Nerv Ment Dis* 2014; 202(1):4-5. (PMID: 24375204).

Workshops & Invited Speeches

1. Fischer, B.A. "A look at American Psychiatry through its diagnoses: The history and development of the *Diagnostic and Statistical Manual of Mental Disorders* (DSM)". The Sheppard and Enoch Pratt Hospital Grand Rounds. June 2004, Baltimore, MD.
2. Fischer, B.A. "Research ethics: The documents you need to know!". The University of Maryland School of Medicine Department of Psychiatry Grand Rounds. May 2006, Baltimore, MD.
3. Baron, D.A., Bhanji, N.H., Fischer, B.A., Goin, M., Gross, L., Slaby, A., and Sumner, C. "Direct to consumer marketing: Just who is the consumer?" Workshop at the annual meeting of the American Psychiatric Association (APA). May 2006, Toronto, Canada.
4. Fischer, B.A. "Informed Consent Research in Schizophrenia." Presented at the Maryland Psychiatric Research Center, Outpatient Research Program's Annual Fall Reception for Patients and Families. October 2009, Baltimore, MD.
5. Fischer, B.A. "Parsimony in treatment of PTSD with alcohol use disorders: What can Topiramate do?" Presented at the VISN 5 MIRECC Science Meeting, Department of Veterans Affairs. February 2010, Baltimore, MD.
6. Fischer, B.A. "The Importance of Sustained Consent in Clinical Trials in Schizophrenia: Evidence of Continuing Capacity to Consent." Presented at the New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting, NIMH and American Society of Clinical Psychopharmacology (ASCP). June 2010, Boca Raton, FL.
7. Himelhoch, S., Slade, E., Dixon, L., Kreyenbuhl, J. and Fischer, B. "Psychotropic Prescribing Patterns for PTSD among VISN 5 Patients in the US Department of Veterans Affairs." Presented at the annual meeting of International Society for Traumatic Stress Studies. November 2010, Montreal, Canada.
8. Keller, W.R., Fischer, B.A., Meyer, W., Reed, M., Blake, M., McMahon, R., and Buchanan, R.W. "Second generation antipsychotics in community treatment for schizophrenia." *Schizophr Bull* 2011; 37(S1):98. Presented at the Thirteenth International Congress on Schizophrenia Research. April 2011, Colorado Springs, CO.

9. Fischer, B.A. Invited Speaker, Certificate Ceremony (recognizing completion of residency) for University of Maryland/Sheppard Pratt Residency in Psychiatry. June 2011, Baltimore, MD.
10. Fischer, B.A. "People with schizophrenia retain capacity to consent during clinical trials." Presented at the VISN 5 MIRECC Science Meeting, Department of Veterans Affairs. May 2012, Baltimore, MD.
11. Gorelick, D., Fischer, B., McMahon, R., Kelly, D., Meyer, W., Wehring, H., Feldman, S., Carpenter, W. "Risk-taking and gambling behavior in schizophrenia and controls with and without cannabis dependence." Presented at the Eleventh World Congress of Biological Psychiatry. June 2013, Kyoto, Japan.
12. Fischer, BA. "Medical ethics." Continuing medical education seminar, NATO Role III Hospital, Kandahar Airfield. May 2014, Kandahar, Afghanistan.
13. Fischer, BA. "Suicide." All-hands (hospital-wide) presentation, NATO Role III Hospital, Kandahar Airfield. May 2014, Kandahar, Afghanistan.
14. Fischer, BA, Hake, S. "PTSD." All-hands (hospital-wide) presentation, NATO Role III Hospital, Kandahar Airfield. August 2014, Kandahar, Afghanistan.

Proffered Communications/Unpublished Scientific Poster Sessions.

1. Fischer IV BA: End-of-life issues from a first-year medical student perspective: Opinions and influences. (Presented at the annual meeting of the American Society for Bioethics and Humanities [ASBH], October 1999, Philadelphia, PA.)
2. Levenson JL, Olbrisch ME, Kulstad JL, Fischer BA: Psychosocial evaluation of organ transplant candidates: Comparative surveys of process criteria and outcomes 1989 and 2000. (Presented at the annual meeting of the Academy of Psychosomatic Medicine, November 2001, San Antonio, TX.)
3. Fischer IV BA, Prentice KJ, Carpenter Jr WT: Ensuring informed consent in research with co-occurring serious mental illness and substance use disorders: the modified Evaluation to Sign Consent. (Presented at the inaugural University of Maryland Patient Safety Symposium, January 2007, Baltimore, MD & at the annual Guze Symposium on Alcoholism, February 2007, St. Louis, MO.)
4. Fischer BA, Rowland LM, Buchanan RW: Proposed safety and biomarker study of acamprosate in schizophrenia. (Presented at the annual New Clinical Drug Evaluation Unit [NCDEU] meeting, June 2007, Boca Raton, FL.)
5. Fischer BA, Rowland LM, Holcomb HH, Buchanan RW. History of alcohol use disorder associated with higher glutamatergic metabolites in the anterior cingulate region of people with schizophrenia. (Presented at the annual meeting of the American College of Neuropsychopharmacology [ACNP], December 2009, Hollywood, FL.)
6. Fischer BA, Keller WR, Arango C, Pearlson G, McMahon RP, Meyer W, Francis A, Kirkpatrick B, Carpenter WT, Buchanan RW. Cortical structural abnormalities in deficit versus nondespite schizophrenia. (Presented at the annual meeting of the American College of Neuropsychopharmacology [ACNP], December 2010, Miami Beach, FL.)
7. Fischer BA, Rowland LM, Keller WR, Holcomb HH, Buchanan RW. Acamprosate acts as a partial agonist of the NMDA receptor: Evidence from a spectroscopy study in schizophrenia. (Presented at the annual meeting of the American College of Neuropsychopharmacology [ACNP], December 2011, Waikoloa Beach, HI.)
8. Vidal C, Reese C, Fischer BA, Chiappelli J, Ramos P, Himelhoch S. Mirtazepine as an adjunctive treatment for negative symptoms in schizophrenia [a meta-analysis]. (Presented at the annual meeting of the American Psychiatric Association [APA], May 2012, Philadelphia, PA.)

9. Marciano R, Nagaraj V, Gillman S, Lennon C, Uyanwune I, Fischer BA. Cannabis Anyone? A review of the effects of cannabis on various organ systems. (Presented at the annual meeting of the American Academy of Addiction Psychiatry [AAAP], December 2012, Miami, FL.)
10. Fischer BA, McMahon RP, Kelly DL, Wehring HJ, Meyer WA, Feldman S, Carpenter WT, Gorelick DA. Risk-taking behavior in schizophrenia and controls with and without cannabis dependence. (Presented at the annual meeting of the American College of Neuropsychopharmacology [ACNP], December 2012, Hollywood, FL.)
11. Gorelick DA, Fischer BA, McMahon RP, Kelly DL, Meyer WA, Wehring HJ, Feldman SM, Carpenter WT. Pathological gambling in people with schizophrenia and cannabis abuse. (Presented at the annual meeting of the American Psychiatric Association [APA], May 2013, San Francisco, CA.)
12. Marciano R, Gillman S, Jeurling S, Polley, S, Stock V, Schloesser R, Kushalani S, Welsh C, Gandhi D, Arana G, Sandson N, Fischer B. Cannabis and drug-drug interactions. (Presented at the annual meeting of the American Psychiatric Association [APA], May 2013, San Francisco, CA.)
13. Fischer BA, Keller WR, McMahon RP, Meyer WA, Miller M, Buchanan RW. Endothelial function in schizophrenia. (Presented at the annual meeting of the American College of Neuropsychopharmacology [ACNP], December 2013, Hollywood, FL.)
14. Hahn B, Harvey AN, Gold JM, Fischer BA, Keller WR, Ross TJ, Stein EA. Hyperactivation of the default network in people with schizophrenia during cognitive task performance. (Presented at the annual meeting of the Society for Neuroscience, November 2014, Washington, DC.)
15. Thomas MA, Rowland LM, Holcomb HH, Wehring HJ, Fischer BA, West J, Schwarcz R. Oral tryptophan administration in healthy humans: Effects of blood kynurenines and verbal learning. (Presented at the annual meeting of the Society for Neuroscience, November 2014, Washington, DC.)
16. Hahn B, Harvey A, Fischer BA, Keller WR, Ross T, Stein E. Nicotinic modulation of the default network of resting brain function in non-smokers. (Presented at the annual meeting of the American College of Neuropsychopharmacology [ACNP], December 2014, Phoenix, AZ.)
17. Wehring H, Heishman S, McMahon R, Turner H, Sullivan K, Fischer B, Rowland L, Bordnick P, Holcomb H, Kearns A, Liu F, Kelley D. Assessment of craving using virtual reality in cannabis users with schizophrenia. (Presented at the annual meeting of the American College of Neuropsychopharmacology [ACNP], December 2014, Phoenix, AZ.)
18. Fischer BA. Prevalence of new-onset psychosis in U.S. Service Members deployed to Kandahar, Afghanistan: Implications for training psychiatric technicians. (Presented as a 'Hot Topic' at the annual meeting of the American College of Neuropsychopharmacology [ACNP], December 2014, Phoenix, AZ.)